%PDF-1.4
%
41 0 obj
<>
endobj
38 0 obj
<>
endobj
102 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-03-02T11:12:46Z
2024-03-28T16:31:28-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T16:31:28-07:00
application/pdf
Heather
2003-122.april
uuid:f7eb27e1-1dd1-11b2-0a00-500927bd7200
uuid:f7eb27e4-1dd1-11b2-0a00-880000000000
endstream
endobj
27 0 obj
<>
endobj
28 0 obj
<>
endobj
42 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
112 0 obj
[116 0 R]
endobj
113 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:4)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(810)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
[(gamma globulin therapy in acute Kawasaki disease. )54.8 (Arch Pediatr)]TJ
0 -1.25 TD
(Adolesc Med 2000;154:694-9.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Maury CP)110.7 (, Salo E, Pelkonen P)110.7 (. Elevated circulating tumor necrosis)]TJ
-0.0002 Tc 0 Tw 1.675 -1.25 Td
[(factor)19.6 (-)]TJ
/T1_3 1 Tf
0 Tc (\002)Tj
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 3.5499 0 Td
(in patients with Kawasaki disease. J Lab Clin Med)Tj
0 Tc 0 Tw -3.5499 -1.25 Td
[(1989;1)36.9 (13:651-4.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Matsubara )17.7 (T)74 (, Furukawa S, )36.8 (Y)99.8 (abuta K. Serum levels of tumor)]TJ
1.675 -1.25 Td
[(necrosis factor)39.7 (, interleukin 2 receptor)39.7 (, and interferon-)]TJ
/T1_3 1 Tf
0 Tc 0 Tw [0.1 (\003)]TJ
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 22.1886 0 Td
(in Kawasaki)Tj
-22.1887 -1.25 Td
(disease involved coronary-artery lesions. Clin Immunol)Tj
T*
(Immunopathol 1990;56:29-36.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Leung DY)128.8 (, Cotran RS, Kurt-Jones E, Burns JC, Newbur)17.7 (ger JW)91.7 (,)]TJ
1.675 -1.25 Td
(Pober JS. Endothelial activation in the pathogenesis of Kawasaki)Tj
-0.0298 Tw T*
[(disease. )-37.1 (T)35 (rans Assoc Am )-54.8 (Physicians )-54.8 (1989;102:131-8.)]TJ
0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (Leung DY)128.8 (, Geha RS, Newbur)17.7 (ger JW)91.7 (, et al. )17.7 (T)69.9 (wo monokines, )]TJ
1.675 -1.25 Td
[(interleukin 1 and tumor necrosis factor)39.7 (, render cultured vascular)]TJ
T*
(endothelial cells susceptible to lysis by antibodies circulating)Tj
T*
(during Kawasaki syndrome. J Exp Med 1986;164:1958-72.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Leung DY)128.8 (, Cotran RS, Kurt-Jones E, Burns JC, Newbur)17.7 (ger JW)91.7 (,)]TJ
1.675 -1.25 Td
(Pober JS. Endothelial cell activation and high IL-1 secretion in the)Tj
T*
(pathogenesis of acute Kawasaki disease. Lancet 1989;2:1298-302.)Tj
31.325 22.5 Td
[(8.)-875.1 (Kalden JR. )17.7 (The application of infliximab \(Remicade\250\), a chimeric)]TJ
1.675 -1.25 Td
[(monoclonal antibody)64.8 (, in the treatment of rheumatic diseases. Isr)]TJ
T*
[(Med )54.9 (Assoc J 2000;2 Suppl:1)36.8 (1-2.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Ruderman EM. Reshaping the treatment pyramid in rheumatoid)]TJ
1.675 -1.25 Td
[(arthritis with biologic response modifiers. )54.8 (Adv Immunotherapy)]TJ
0 Tw T*
[(2002;9:5-1)36.8 (1.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Kato H, Koike S, )36.8 (Y)99.8 (okoyama )17.7 (T)74 (. Kawasaki disease: ef)17.7 (fect of )]TJ
2.175 -1.25 Td
(treatment on coronary artery involvement. Pediatr 1979;63:175-9.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (W)39.8 (right DA, Newbur)17.7 (ger JW)91.7 (, Baker )54.8 (A, Sundel RP)110.7 (. Clinical and )]TJ
2.1381 -1.25 Td
(laboratory observations of immune globulin-resistant Kawasaki)Tj
T*
(disease with pulsed doses of corticosteroids. J Pediatr)Tj
0 Tc 0 Tw T*
(1996;128:146-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Hashino K, Ishii M, Iemura M, )54.8 (Akagi )17.7 (T)74 (, Kato H. Re-treatment for)]TJ
2.175 -1.25 Td
(immune globulin-resistant Kawasaki disease: a comparative study)Tj
T*
[(of additional immune globulin and steroid pulse therapy)64.8 (. Pediatr Int)]TJ
0 Tc 0 Tw T*
[(2001;43:21)36.9 (1-7.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
21 0 obj
<>stream
8;Z\5!>:#=#ikq,j?&h]!G^lKS'Kb@\]qIC`$)'fpD%WMs#^h@A]q>goO`_\#cdc3?#@/gneMU"LFdS-$182[%Qo]-s-cU3N
i2B!MN@fp-.5k>^2s!FWf[r-u3qNe@=(S5ASU;o,+)ShI/o4C#2j@--=+.[WE,!0(
;N6C,(E_pnrN+:*QA
p-Of"'TrpFZar46]iQr;NQ2#TW3Uj~>
endstream
endobj
25 0 obj
[/Indexed/DeviceRGB 255 24 0 R]
endobj
24 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
95 0 obj
<>
endobj
44 0 obj
<>
endobj
51 0 obj
<>
endobj
53 0 obj
<>
endobj
88 0 obj
<>
endobj
107 0 obj
<>
endobj
54 0 obj
<>
endobj
49 0 obj
<>
endobj
48 0 obj
<>stream
HTP=o ԁD1npתi'DHLJԁ'g^koT 0 e %(Fuof]Gg,pv=Ku%ze8}HshT9H Fw5rfC+qu@?r@#H{(HU]H)мD49>&m%WN_䗖+6&By42<.M` sD
endstream
endobj
52 0 obj
<>stream
KGJDHG+Symbol / H H alphagammaSymbol ag &